NICE rethinks gudiance on Sanofi-Aventis's Multaq
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, has reconsidered its preliminary negative recommendations on Sanofi-Aventis's Multaq (dronedarone) for patients with atrial fibrillation (AF). Concerns from patients and clinicians seem to have swayed the institute.
You may also be interested in...
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.